Transaction Overview - CoreWeave will acquire Core Scientific in an all-stock transaction at a fixed exchange ratio of 0.1235 CoreWeave share per Core Scientific share[9] - The acquisition is expected to result in CoreWeave owning less than 10% of the combined entity at close[9] - The deal is expected to close in Q4 2025, subject to regulatory approval and customary closing conditions[9] Financial Impact and Synergies - The acquisition is projected to immediately eliminate over $10 billion in future lease overhead for existing contractual sites[9] - CoreWeave anticipates over $500 million in fully ramped, annual run rate cost savings by the end of 2027 through streamlined operations[9, 22] - The transaction is expected to be leverage neutral, while providing access to diverse financing sources at a more attractive cost of capital[9] Assets and Capacity - Core Scientific's assets include over $760 million in fixed assets and right-of-use assets, and over $770 million of cash and liquid digital assets[10] - Core Scientific has a current portfolio of 1.3GW of power capacity with over 1GW of potential expansion gross power available[10] - Core Scientific has approximately 500MW of mining data center gross power capacity, which can be optionally converted to HPC[11] Strategic Benefits - The acquisition will give CoreWeave direct control over approximately 1.3GW+ of gross power, with the majority already under CoreWeave contract[18] - CoreWeave can unlock approximately $5B of committed capex for more efficient financing[25] - CoreWeave will gain greater control over a critical power footprint and optionality for future power capacity[15]

Bezuclastinib Program - Bezuclastinib is a potential best-in-class selective KIT mutant inhibitor, showing promise in pre-clinical studies and Phase 1/2 trials for GIST patients[10, 115] - KIT mutations drive up to 80% of GIST and over 90% of SM cases[27] - Bezuclastinib exhibits minimal brain penetration, with a brain to plasma ratio of 007, compared to 20 for avapritinib[37] - Cogent is conducting a Phase 2 clinical study (APEX) of Bezuclastinib in patients with Advanced Systemic Mastocytosis, with initial clinical results expected in 1H 2022[47, 48] FGFR2 Program - FGFR2 and FGFR3 are collectively altered in up to 41% of cancers[55] - Cogent is developing FGFR2 selective inhibitors with a target profile of <10 nM FGFR2 Cell IC50 and >200 nM FGFR1 Cell IC50[64] - CGT0292, a lead compound, demonstrates ~30x selectivity between FGFR1 and FGFR2 in cellular assays[80] - CGT0292 does not show serum phosphorus increase at a 5 mg/kg dose in the SD Rat Model of Hyperphosphatemia[84] ErbB2 Program - Significant unmet need remains for patients with non-exon 20 ErbB2 mutations[95] - Cogent is developing an ErbB2 mutant selective drug which covers key mutations while sparing wtEGFR, with a target Mutant Cell IC 50 of <10 nM and EGFR WT Cell IC 50 of >200 nM[104, 105] - Cogent has identified several novel series with promising enzyme selectivity for ErbB2 over EGFR WT[114] Financial Status - Cogent Biosciences had a cash balance of $2197 million as of December 31, 2021[12, 117]

Bezuclastinib Clinical Programs - Bezuclastinib combined with sunitinib demonstrated a 12-month median Progression-Free Survival (mPFS) in heavily pre-treated Gastrointestinal Stromal Tumors (GIST) patients[10] - In the APEX study, initial data in Advanced Systemic Mastocytosis (AdvSM) patients shows promising clinical activity with Bezuclastinib[10] - In Apex study, the Overall Response Rate (ORR) of CR + CRh + PR + CI was 73% (8 out of 11 patients) per CRRC assessment in TKI therapy-naïve AdvSM patients[27] - In Apex study, 88% of patients achieved a ≥ 50% reduction in serum tryptase levels[35] - In Apex study, 100% of patients with at least 2 cycles of treatment achieved a ≥ 50% reduction in bone marrow mast cell burden[35] - In Apex study, 92% of patients with at least 2 cycles of treatment achieved a ≥ 50% reduction in KIT D816V VAF[35] Market Opportunity - The global Total Addressable Market (TAM) potential for Bezuclastinib exceeds $3.5 billion, including $1.5 billion for NonAdvSM, $700 million for 2nd-line GIST, and $300 million for AdvSM[14] - Approximately 90% of Systemic Mastocytosis (SM) patients present with non-advanced systemic mastocytosis (NonAdvSM)[18] - Approximately 10% of patients present with advanced systemic mastocytosis (AdvSM)[18] Pipeline and Financials - The company's research pipeline includes novel, small-molecule targeted therapies for rare diseases, including an FGFR1-sparing, pan-mutant FGFR2 and a CNS-penetrant ErbB2[7] - The company's cash runway is expected to fund operations into 2025, with $289.1 million in cash as of September 30, 2022[7, 83]

Sebetralstat Overview - Sebetralstat, if approved, is poised to be the first oral on-demand treatment for Hereditary Angioedema (HAE), potentially transforming the global treatment landscape[20, 22] - Clinical data shows the safety profile of Sebetralstat is no different from placebo, with robust efficacy demonstrated across all attack types, severities, and locations[18, 129] - The median time to beginning of symptom relief was 161 hours for 300 mg and 179 hours for 600 mg of sebetralstat, compared to 672 hours for placebo in Phase III trials[67] - In an open-label extension study, the median time to treatment was 10 minutes overall, 20 minutes for abdominal attacks, and 115 minutes for laryngeal attacks[72] Market Opportunity - The current global HAE market is valued at $13 billion, with a $3 billion global on-demand opportunity[23] - The on-demand market is projected to increase by 70%, driving the global sales to over $4 billion by 2030[89] - In the U S, approximately 84,000 on-demand doses are utilized, with 70% of attacks treated with Firazyr or icatibant[98, 99] Commercialization Strategy - KalVista plans to launch Sebetralstat in the US by June 2025, followed by Germany in 2H 2025, and the UK and Japan in 1H 2026[20, 123] - The company anticipates broad payor access, primarily through commercial coverage, with pricing comparable to existing branded therapies, ranging from $11,000 to $16,000 per attack[17, 110] - KalVista is targeting the top 1,000 HCPs and is focusing on patients currently using Firazyr and icatibant to drive early demand and accelerate adoption[126]

UroGen's Pipeline and Market Opportunity - UroGen is positioned to transform bladder cancer treatment with JELMYTO, UGN-102, and UGN-301 [3, 7] - UGN-102 may become the first FDA-approved medicine for LG-IR-NMIBC [9] - The total addressable market (TAM) for LG-IR-NMIBC is estimated to be over $5 billion [9, 120] - Approximately 82,000 patients in the U S have LG-IR-NMIBC annually [9, 120] UGN-102 Clinical Trial Results (ENVISION Study) - The complete response rate (CRR) at 3 months in the ENVISION study was 796% (191/240 patients) [44, 55, 115] - The estimated duration of response (DOR) at 12 months was 823% (N=191) [57, 70, 117] - The predicted median duration of response (DOR) is 400 months [61, 63] - The majority of adverse events (AEs) were mild to moderate in severity [64, 65] Patient Perceptions of UGN-102 vs TURBT - Interviews with 29 U S patients from the ENVISION study revealed that UGN-102 was perceived to be less invasive, painful, and time-consuming compared to TURBT [80, 86] - Patients reported that UGN-102 had less impact on daily activities and responsibilities compared to TURBT [86, 90]

Resource Highlights - Total Measured and Indicated (M&I) Gold Resources are 106 million ounces [11] - Total Inferred Gold Resources are 34 million ounces [11] - Total M&I Silver Resources are 361 million ounces [11] - Total Inferred Silver Resources are 96 million ounces [11] - Total M&I Gold Equivalent Resources are 152 million ounces [14] - Total Inferred Gold Equivalent Resources are 46 million ounces [14] - The resource area comprises less than 10% of the company's land package [22, 40, 44, 85] Financial Position - Cash position was approximately $397 million as of March 31, 2025 [9, 24] - An additional $277 million was held as restricted cash [24] Exploration and Development - The company has made a new high-grade silver discovery [9, 22, 33] - Average flotation recoveries are 10% higher than previously modeled, with 89% gold and 93% silver recovery [33]

Financial Performance & Market Position - Novocure reported 2024 net revenue of $605 million[13] - The company has over 4,000 global active patients on therapy[13] - Novocure has established a strong foundation and is building towards profitability[13] Clinical Pipeline & Development - Novocure has commercially launched in Non-Small Cell Lung Cancer (NSCLC)[15] - Positive Phase 3 data was reported in Brain Metastases from NSCLC and Locally Advanced Pancreatic Cancer[15] - Regulatory submissions for Brain Metastases from NSCLC (METIS) and Locally Advanced Pancreatic Cancer (PANOVA-3) are planned for H2 2025[17, 28] - The company is advancing label-expanding clinical trials and investing in its platform for future expansion opportunities[31] Clinical Trial Results - The PANOVA-3 Phase 3 clinical trial showed a statistically significant improvement in pain-free survival, with a median pain-free survival of 15.2 months in the TTFields + GnP group compared to 9.1 months in the GnP group (HR = 0.74)[24, 25] - The one-year pain-free survival rate in the TTFields + GnP group was 54.1%[25] Key Objectives - Novocure aims to drive global active patient growth in NSCLC and pursue reimbursement[30]

Financial Performance - Pre-tax, pre-provision income increased by 14.2% year-over-year to $64.8 million[4] - Net income available to common shareholders was $50.6 million, with diluted EPS of $0.76[4] - Mortgage banking income increased significantly by 84.0% year-over-year to $5.4 million[4] - The efficiency ratio improved to 57.06%[4] Balance Sheet and Loan Portfolio - Total risk-based capital ratio was 17.57%[3] - Loan growth was 5.1% year-over-year, including approximately $726.3 million in SBA PPP loans[4] - Deposit growth (excluding CDs) was 20.8% year-over-year[4] - Q4 residential real estate loan levels were impacted by retaining a smaller percentage of the $351 million of Q4 mortgage origination dollar volume (~50% refi) on the balance sheet[11] - Q4 consumer loans declined 17.6% YoY reflecting payoffs driven by utilization of residential mortgage refinancing and higher personal savings[11] Asset Quality and Credit Loss - Non-performing assets to total assets ratio was 0.25%[6] - Net loan charge-offs to average loans (annualized) was 0.02%[6] - Allowance for credit losses as a percentage of total loans was 1.72%, or 1.85% excluding SBA PPP loans[42] Customer Support and Deferrals - Pandemic-related loan deferral balances decreased by approximately 90% from the May 2020 peak, reaching $171 million as of December 31, 2020[15]

Financial Performance - Pre-tax, pre-provision income was $57.8 million[5] - Net income available to common shareholders was $45.4 million, with diluted EPS of $0.70 per share[5] - The efficiency ratio year-to-date was 57.04%[5] - Return on average tangible equity was 11.57% for the quarter ending September 30, 2021[6] Balance Sheet and Loan Portfolio - Deposit growth, excluding certificates of deposit, increased by 15.0% year-over-year[5] - Non-performing assets to total assets stood at 0.24%[5] - Approximately 21 million shares of WesBanco common stock were repurchased during the quarter[5] - Remaining SBA PPP loans totaled approximately $272 million as of September 30, 2021[9] Net Interest Margin and Non-Interest Income - Investment securities increased by $1.1 billion year-over-year, representing approximately 23% of total assets[14] - Total non-interest income was $32.755 million[15] - Trust fees increased by 13.4% due to net organic growth in trust assets under management ($5.5 billion)[15]

Company Overview and Strategy - VolitionRx focuses on advancing low-cost, early detection, and treatment monitoring tests in cancer and sepsis[7] - The company's strategy involves licensing its IP to major players, following a low CapEx/low OpEx model similar to its Nu.Q® Vet business[11, 20] - Volition aims to be cash neutral on a full-year basis in 2025, balancing income with expenditure[87] Veterinary Commercial Progress - The Nu.Q® Vet Cancer test is available in over 20 countries[20] - Approximately 120,000 Nu.Q® Vet Cancer tests and test components were sold in 2024[20, 39] - The company has received $23 million in upfront and milestone payments to date, with an additional $5 million milestone payment anticipated in 2025[20] Expansion into Human Diagnostics - Volition is targeting licensing deals in the human sepsis and cancer space in 2025[10] - The company sees a $4 billion opportunity in lung cancer screening, prognostics, and MRD, and a $1 billion+ opportunity in sepsis testing and monitoring[21] - First revenue was recorded for CE-marked product in Q1 2025[85] Financial Performance - Volition recorded approximately $0.25 million in revenue in Q1 2025, a 44% increase over the first quarter of the prior year[87] - Net cash used in operating activities averaged $1.4 million a month, almost 50% lower than the first quarter of 2024[87]